• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞核因子1α突变型肝细胞腺瘤:一种非典型表现。

Hepatocyte Nuclear Factor 1α-Mutated Hepatocellular Adenomas: An Atypical Presentation.

作者信息

Sousa Camila Maria Neves, Gadelha Patricia Maria Miranda, Cartaxo Rafaella de Sousa, Pedrosa George Washington Holanda, Honorio Rodrigo Schuler, Lima José Milton de Castro, Coelho Gustavo Rêgo, Coelho Clovis Rêgo

机构信息

São Carlos Institute of Education and Research, Farias Brito Faculty, Fortaleza, Brazil.

Hospital Infantil Albert Sabin, Fortaleza, Brazil.

出版信息

Case Rep Gastroenterol. 2017 Oct 30;11(3):637-642. doi: 10.1159/000480376. eCollection 2017 Sep-Dec.

DOI:10.1159/000480376
PMID:29282384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5731146/
Abstract

Hepatocellular adenomas (HCAs) are rare benign monoclonal hepatic tumors that commonly occur in females (3-4 per 100,000 women) due to the use of oral contraceptives, its primary risk factor. Recently, HCAs have been classified into 4 distinct subtypes according to genotypic and phenotypic characteristics and clinical features: inflammatory HCA (40-50%), which are hypervascular with marked peliosis and a tendency to bleed; hepatocyte nuclear factor 1α (HNF1A)-mutated HCA (H-HCA, 30-40%) that are diffusely steatotic and rarely undergo malignant transformation; β-catenin activated HCA (10-15%), which frequently undergo malignant transformation and may seem hepatocellular carcinoma on imaging; and unclassified HCA (10-25%). In this study, we report the case of a 23-year-old female oral contraceptive user with H-HCA. Usually, H-HCA is considered to be nonsevere in most cases and often requires outpatient follow-up. However, in this case, the injury had substantially increased in volume and evolved with a major bleeding frame, which was an unusual finding for this subtype of adenoma. The therapeutic used for this patient was a laparoscopic left hepatic segmentectomy. Thus, the choice of treatment to be performed in a patient with H-HCA can depend on the tumor size (>5 cm), the outcome of previous bleeding, and the risk of bleeding recurrence.

摘要

肝细胞腺瘤(HCAs)是一种罕见的良性单克隆性肝肿瘤,由于其主要危险因素——口服避孕药的使用,常见于女性(每10万名女性中有3 - 4例)。最近,HCAs根据基因型、表型特征和临床特点被分为4种不同亚型:炎症性HCA(40 - 50%),具有高血供,伴有明显的血囊肿,并有出血倾向;肝细胞核因子1α(HNF1A)突变型HCA(H - HCA,30 - 40%),弥漫性脂肪变性,很少发生恶性转化;β-连环蛋白激活型HCA(10 - 15%),经常发生恶性转化,在影像学上可能类似肝细胞癌;以及未分类的HCA(10 - 25%)。在本研究中,我们报告了一例使用口服避孕药的23岁女性患有H - HCA的病例。通常,大多数情况下H - HCA被认为病情不严重,常需门诊随访。然而,在该病例中,损伤体积显著增大,并伴有严重出血表现,这对于该亚型腺瘤来说是不寻常的发现。对该患者采用的治疗方法是腹腔镜左肝段切除术。因此,对于H - HCA患者的治疗选择可能取决于肿瘤大小(>5 cm)、既往出血情况以及出血复发风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72e1/5731146/82b1489de0d6/crg-0011-0637-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72e1/5731146/51255295bba7/crg-0011-0637-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72e1/5731146/82b1489de0d6/crg-0011-0637-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72e1/5731146/51255295bba7/crg-0011-0637-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72e1/5731146/82b1489de0d6/crg-0011-0637-g02.jpg

相似文献

1
Hepatocyte Nuclear Factor 1α-Mutated Hepatocellular Adenomas: An Atypical Presentation.肝细胞核因子1α突变型肝细胞腺瘤:一种非典型表现。
Case Rep Gastroenterol. 2017 Oct 30;11(3):637-642. doi: 10.1159/000480376. eCollection 2017 Sep-Dec.
2
Current updates on the molecular genetics and magnetic resonance imaging of focal nodular hyperplasia and hepatocellular adenoma.局灶性结节性增生和肝细胞腺瘤的分子遗传学与磁共振成像的最新进展
Insights Imaging. 2015 Jun;6(3):347-62. doi: 10.1007/s13244-015-0399-8. Epub 2015 Mar 20.
3
Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.肝细胞腺瘤的分子分类与危险因素、出血和恶性转化相关。
Gastroenterology. 2017 Mar;152(4):880-894.e6. doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7.
4
Subtype classification of hepatocellular adenoma.肝细胞腺瘤的亚型分类。
Dig Surg. 2010;27(1):39-45. doi: 10.1159/000268406. Epub 2010 Apr 1.
5
Hepatocellular adenomas: review of pathological and molecular features.肝细胞腺瘤:病理和分子特征综述。
Hum Pathol. 2021 Jun;112:128-137. doi: 10.1016/j.humpath.2020.11.016. Epub 2020 Dec 9.
6
Hepatocellular adenoma management: call for shared guidelines and multidisciplinary approach.肝细胞腺瘤的管理:呼吁制定共享指南和采取多学科方法。
Clin Res Hepatol Gastroenterol. 2015 Apr;39(2):180-7. doi: 10.1016/j.clinre.2014.10.003. Epub 2014 Nov 26.
7
Steatotic hepatocellular adenomas with different phenotypic subtypes: a case report.具有不同表型亚型的脂肪变性肝细胞腺瘤:一例报告
Clin Res Hepatol Gastroenterol. 2015 Apr;39(2):e17-22. doi: 10.1016/j.clinre.2014.08.007. Epub 2014 Sep 26.
8
Hepatocellular adenoma: what is new in 2008.肝细胞腺瘤:2008 年的新进展。
Hepatol Int. 2008 Sep;2(3):316-21. doi: 10.1007/s12072-008-9075-0. Epub 2008 May 1.
9
Hepatocellular adenoma: An unsolved diagnostic enigma.肝细胞腺瘤:一个尚未解决的诊断难题。
World J Gastroenterol. 2019 May 28;25(20):2442-2449. doi: 10.3748/wjg.v25.i20.2442.
10
Hepatocellular adenoma in the paediatric population: Molecular classification and clinical associations.儿童肝腺瘤:分子分类和临床关联。
World J Gastroenterol. 2020 May 21;26(19):2294-2304. doi: 10.3748/wjg.v26.i19.2294.

本文引用的文献

1
Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis.肝细胞腺瘤分类:免疫组织化学与靶向突变分析的比较评估
Diagn Pathol. 2016 Mar 9;11:27. doi: 10.1186/s13000-016-0475-5.
2
Current updates on the molecular genetics and magnetic resonance imaging of focal nodular hyperplasia and hepatocellular adenoma.局灶性结节性增生和肝细胞腺瘤的分子遗传学与磁共振成像的最新进展
Insights Imaging. 2015 Jun;6(3):347-62. doi: 10.1007/s13244-015-0399-8. Epub 2015 Mar 20.
3
Hepatocellular adenoma management: call for shared guidelines and multidisciplinary approach.
肝细胞腺瘤的管理:呼吁制定共享指南和采取多学科方法。
Clin Res Hepatol Gastroenterol. 2015 Apr;39(2):180-7. doi: 10.1016/j.clinre.2014.10.003. Epub 2014 Nov 26.
4
Pictures of focal nodular hyperplasia and hepatocellular adenomas.局灶性结节性增生和肝细胞腺瘤的图片。
World J Hepatol. 2014 Aug 27;6(8):580-95. doi: 10.4254/wjh.v6.i8.580.
5
Diagnosis and management of solid benign liver lesions.肝脏固体良性病变的诊断与处理。
Nat Rev Gastroenterol Hepatol. 2014 Dec;11(12):737-49. doi: 10.1038/nrgastro.2014.151. Epub 2014 Sep 2.
6
Risk factors for bleeding in hepatocellular adenoma.肝细胞腺瘤出血的风险因素。
Br J Surg. 2014 Jun;101(7):847-55. doi: 10.1002/bjs.9493. Epub 2014 Apr 24.
7
Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.对肝细胞腺瘤的基因组分析揭示了 FRK 激活突变的重现和恶性转化的机制。
Cancer Cell. 2014 Apr 14;25(4):428-41. doi: 10.1016/j.ccr.2014.03.005.
8
Expert perspectives on evidence-based treatment planning for patients with hepatocellular carcinoma.肝细胞癌患者循证治疗规划的专家观点
Cancer Control. 2014 Apr;21(2 Suppl):5-16. doi: 10.1177/1073274814021002s02.
9
Hepatocellular benign tumors-from molecular classification to personalized clinical care.肝细胞良性肿瘤——从分子分类到个体化临床治疗。
Gastroenterology. 2013 May;144(5):888-902. doi: 10.1053/j.gastro.2013.02.032. Epub 2013 Feb 26.
10
Systematic review of haemorrhage and rupture of hepatocellular adenomas.系统综述肝细胞腺瘤的出血和破裂。
Br J Surg. 2012 Jul;99(7):911-6. doi: 10.1002/bjs.8762. Epub 2012 May 22.